Roberts SA, Lawrence MS, Klimczak LJ, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013;45(9):970-6. doi:10.1038/ng.2702
Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45(10):1134-40. doi:10.1038/ng.2760
Ran A, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281-308. doi:10.1038/nprot.2013.143
Kaufmann BB, Hung DT. The fast track to multidrug resistance. Mol Cell. 2010;37(3):297-8. doi:10.1016/j.molcel.2010.01.027
Xue W, Chen S, Yin H, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 2014;514(7522):380-4. doi:10.1038/nature13589
Dumanski JP, Rasi C, Lönn M, et al. Mutagenesis. Smoking is associated with mosaic loss of chromosome Y. Science. 2015;347(6217):81-3. doi:10.1126/science.1262092
Israelsen WJ, Dayton TL, Davidson SM, et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell. 2013;155(2):397-409. doi:10.1016/j.cell.2013.09.025
Chan K, Roberts SA, Klimczak LJ, et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet. 2015;47(9):1067-72. doi:10.1038/ng.3378
Kiani S, Chavez A, Tuttle M, et al. Cas9 gRNA engineering for genome editing, activation and repression. Nat Methods. 2015;12(11):1051-4. doi:10.1038/nmeth.3580
Canver MC, Smith EC, Sher F, et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature. 2015;527(7577):192-7. doi:10.1038/nature15521